Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Impedimed Limited ( (AU:IPD) ).
Impedimed Limited announced the issuance of 1,278,591 ordinary fully paid shares to non-executive directors as part of their Non-Executive Director Share Plan, covering 30% of director fees for the quarter ending June 30, 2025. This move is part of the company’s ongoing strategy to align the interests of its directors with those of its shareholders, potentially enhancing governance and stakeholder confidence.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited operates in the medical technology industry, focusing on the development and distribution of non-invasive medical devices. The company’s primary products are designed to assess and monitor fluid status and body composition, with a particular emphasis on applications in healthcare settings.
Average Trading Volume: 2,702,662
Technical Sentiment Signal: Hold
Current Market Cap: A$103.4M
For an in-depth examination of IPD stock, go to TipRanks’ Overview page.